Reviews/Alzheimers Disease Treatment/Lecanemab slows decline in early Alzheimer's disease
Amyloid Immunotherapy · AD-AMY-01 · v2
Borderline: within 4 points of the Established/Likely boundary, so a re-grade could land either side.
A large, well-run 18-month trial comparing lecanemab against a dummy treatment in people with early Alzheimer's disease found that those on the drug declined less on a standard measure of thinking and daily function [1]. The same trial's follow-up reported that this benefit continued out to three years [4], and a look at a large subgroup of participants found the same pattern [19]. The honest complication is that almost all of this comes from a single trial, and a separate real-world group of 190 patients saw no measurable benefit [21]. The panel judged that the direction of the effect, which is all the claim asserts, is well demonstrated, while noting the evidence leans heavily on one study and that everyday-practice results are mixed.
The pivotal double-blind trial [1] enrolled 1795 participants and met its primary endpoint, with a CDR-SB difference of -0.45 (95% CI -0.67 to -0.23; P<0.001) favouring lecanemab, consistent across secondary cognitive and functional measures. The open-label extension reported that participants "continued to benefit through 36 months" [4], and the ApoE subgroup analysis found lecanemab "significantly reduced clinical decline on CDR-SB at 18 months compared to placebo" and a 28% lower risk of progression [19]. A retrospective cohort found cognitive decline "less frequent in the lecanemab group (23.5 vs. 81.8%; P < 0.001)" [10]. Against this, a real-world cohort of 190 patients reported "no measurable cognitive efficacy" [21]. The contested point: The division is between trial and real-world settings: the randomised evidence [1], its extension [4] and subgroup [19] all show slowed decline, while an everyday-practice cohort [21] found none. Compounding this, the strongest evidence is one trial (Clarity AD, NCT03887455) re-reported, so apparent breadth is not independent replication.
All 23 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from Alzheimers Disease Treatment, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The strongest evidence ([1], [4], [19]) all derives from a single trial, Clarity AD (NCT03887455); the corpus contains no independent confirmatory RCT, so apparent breadth overstates replication.
A real-world cohort of 190 patients [21] reported no measurable cognitive efficacy, raising external-validity/effectiveness concerns beyond the trial setting.
Where it remains uncertain. A real-world cohort of 190 patients reported "no measurable cognitive efficacy" [21], and the trial evidence is concentrated in a single study [1], [4], [19].
Aleatory
Even where decline is slowed on average [1], outcomes differ across patients, and one real-world cohort saw no measurable benefit [21].
Epistemic
The randomised evidence is one trial re-reported across [1], [4] and [19]; no independent confirmatory RCT is in the corpus.
Inferential
The 36-month benefit [4] is open-label against natural-history cohorts, so causal attribution beyond 18 months is weakened.
The load-bearing papers from a corpus of 23, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Pivotal RCT demonstrating statistically significant slowing of clinical decline on the primary CDR-SB endpoint
“Lecanemab reduced markers of amyloid in early Alzheimer's disease and resulted in moderately less decline on measures of cognition and function than placebo at 18 months but was associated with adverse events.”
Panel auditInternal validity: high · scope of inference: Amyloid-positive persons 50-90 with MCI or mild dementia due to AD, over 18 months.Key limitations: effect size small/modest · 18-month horizon only · adverse events (ARIA, infusion reactions)
Extension showing the slowing persists to 36 months
“Results presented in our paper demonstrate that lecanemab continued suppression of amyloid plaque levels and significantly slowed clinical decline on multiple measures of cognition, function, and quality of life in early AD at 18 months and continued for 36 months to date.”
Panel auditInternal validity: medium · scope of inference: Longer-term (36-month) lecanemab outcomes in early symptomatic AD, including low-pathology subgroup.Key limitations: open-label after 18 months · no concurrent placebo in extension · sponsor-linked authorship
Subgroup replication of the primary clinical finding
“Lecanemab significantly reduced clinical decline on CDR-SB at 18 months compared to placebo in the ApoEε4 heterozygotes or non-carriers subgroup.”
Panel auditInternal validity: high · scope of inference: ApoE ε4 non-carrier/heterozygote early-AD patients (85% of Clarity AD).Key limitations: subgroup analysis · 36-month comparison vs natural history not placebo · sponsor-linked
Independent (non-trial) directional support, non-placebo comparator
“Cognitive decline was less frequent in the lecanemab group (23.5 vs. 81.8%; P < 0.001).”
Panel auditInternal validity: low · scope of inference: AD patients treated 6 months with lecanemab vs dcLVA in one centre.Key limitations: retrospective non-randomised · comparator is another active treatment · short follow-up
4 of 23 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
A well-powered placebo-controlled phase 3 RCT directly and significantly demonstrates slowed clinical decline, outweighing single-trial concentration and one discordant real-world cohort.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
No independent confirmatory RCT. All randomised evidence derives from Clarity AD [1], [4], [19], so the direction of effect has not been reproduced by a separate trial. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A second, independently conducted double-blind placebo-controlled RCT in early AD with CDR-SB as primary endpoint.
Open question: Does an independent trial reproduce the slowed clinical decline seen in Clarity AD? Why it is still open: The corpus's randomised evidence is a single trial re-reported in [1], [4] and [19].
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19